Rights & Society
EMA Recommends New Lung Cancer Treatment
The European Medicines Agency (EMA) has recommended granting marketing authorization for Imdylltra (tarlatamab) in the EU. This monotherapy is intended for treating adults with relapsed extensive-stage small cell lung cancer. The recommendation from the EMA's human medicines committee (CHMP) is a positive step forward in providing new treatment options for lung cancer patients. The European Commission will now review the EMA's recommendation and make a final decision on marketing authorization.
New lung cancer treatment gets EMA nod, expanding therapy options.